ETF Holdings Breakdown of CRSP

Stock Name	Crispr Therapeutics AG
Ticker	CRSP(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	CH0334081137
LEI	506700O6IRRIQLT3W370

News associated with CRSP

Dimensional Fund Advisors LP Has $37.28 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP): Dimensional Fund Advisors LP boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 14.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 947,301 shares of the company’s stock after purchasing an additional 122,695 shares during the quarter. Dimensional […] - 2025-05-05 08:20:52
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Hold” by Analysts: Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have received an average rating of “Hold” from the twenty-one research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eleven have issued a buy recommendation on […] - 2025-05-02 07:20:50
CRISPR Therapeutics AG (NASDAQ:CRSP) Position Raised by NewEdge Advisors LLC: NewEdge Advisors LLC grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 28.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 7,420 shares of the company’s stock after purchasing an additional 1,622 shares during the quarter. NewEdge Advisors LLC’s […] - 2025-05-01 08:37:08
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Invesco Ltd.: Invesco Ltd. raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,790 shares of the company’s stock after purchasing an additional 2,010 shares during the period. Invesco Ltd.’s holdings in CRISPR […] - 2025-05-01 07:42:52
Raymond James Financial Inc. Invests $3.23 Million in CRISPR Therapeutics AG (NASDAQ:CRSP): Raymond James Financial Inc. bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 82,095 shares of the company’s stock, valued at approximately $3,231,000. A number of other institutional investors […] - 2025-04-28 07:51:03
Legal & General Group Plc Has $3.85 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP): Legal & General Group Plc trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 8.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 97,804 shares of the company’s stock after selling 9,121 shares during the quarter. Legal & General […] - 2025-04-23 08:19:07
Wells Fargo & Company MN Buys 17,094 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP): Wells Fargo & Company MN increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 8.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 220,123 shares of the company’s stock after purchasing an additional 17,094 shares during the quarter. Wells Fargo & […] - 2025-04-18 07:36:51
Geode Capital Management LLC Sells 7,346 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP): Geode Capital Management LLC lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 0.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,000,868 shares of the company’s stock after selling 7,346 shares during the period. Geode Capital Management LLC’s holdings in CRISPR Therapeutics were worth $39,412,000 as of its […] - 2025-04-16 07:38:58
Norges Bank Makes New $17.46 Million Investment in CRISPR Therapeutics AG (NASDAQ:CRSP): Norges Bank acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 443,536 shares of the company’s stock, valued at approximately $17,458,000. Norges Bank owned about 0.52% of CRISPR Therapeutics as of its most recent filing with […] - 2025-04-08 08:19:03
Mitsubishi UFJ Asset Management Co. Ltd. Raises Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP): Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.6% in the fourth quarter, HoldingsChannel reports. The firm owned 5,252 shares of the company’s stock after buying an additional 372 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in CRISPR Therapeutics […] - 2025-04-04 08:12:57
KLP Kapitalforvaltning AS Buys New Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP): KLP Kapitalforvaltning AS purchased a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 16,100 shares of the company’s stock, valued at approximately $634,000. A number of other large investors have also bought and sold shares of the stock. Charles Schwab Investment […] - 2025-04-03 07:28:56
Congress Wealth Management LLC DE Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP): Congress Wealth Management LLC DE purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 5,640 shares of the company’s stock, valued at approximately $222,000. Several other hedge funds also recently added to or reduced their […] - 2025-03-31 08:15:00
Corient Private Wealth LLC Has $347,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP): Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 8,827 shares of the company’s stock after selling 365 shares during the period. Corient Private Wealth LLC’s holdings in CRISPR Therapeutics were worth $347,000 as of its most recent […] - 2025-03-31 07:30:54
Avantax Advisory Services Inc. Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP): Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,836 shares of the company’s stock, valued at approximately $269,000. A number of other institutional investors have also modified their […] - 2025-03-26 08:50:59
Harbour Investments Inc. Sells 350 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP): Harbour Investments Inc. reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,717 shares of the company’s stock after selling 350 shares during the period. Harbour Investments Inc.’s […] - 2025-03-24 08:39:11
Zurcher Kantonalbank Zurich Cantonalbank Has $874,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP): Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 22,217 shares of the company’s stock after acquiring an additional 645 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in CRISPR […] - 2025-03-21 09:18:55
Farther Finance Advisors LLC Acquires 977 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP): Farther Finance Advisors LLC boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 34.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,834 shares of the company’s stock after purchasing an additional 977 shares during the period. Farther Finance […] - 2025-03-21 08:27:02
US Bancorp DE Sells 1,380 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP): US Bancorp DE lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 53.3% during the 4th quarter, Holdings Channel reports. The firm owned 1,209 shares of the company’s stock after selling 1,380 shares during the period. US Bancorp DE’s holdings in CRISPR Therapeutics were worth $48,000 at the end of […] - 2025-03-19 07:10:48
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Hold” by Analysts: Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have been assigned a consensus recommendation of “Hold” from the twenty-one ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating […] - 2025-03-13 06:53:04
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by State of New Jersey Common Pension Fund D: State of New Jersey Common Pension Fund D boosted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 10.8% during the 4th quarter, Holdings Channel reports. The fund owned 44,692 shares of the company’s stock after acquiring an additional 4,351 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings […] - 2025-02-26 08:31:02
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4.7% Following Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price was down 4.7% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $45.16 and last traded at $45.65. Approximately 914,670 shares traded hands during mid-day trading, a decline of 62% from the average daily volume […] - 2025-02-26 06:24:52
Allworth Financial LP Purchases 14,398 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP): Allworth Financial LP lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,117.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 15,078 shares of the company’s stock after buying an additional 14,398 shares during the quarter. Allworth Financial LP’s holdings in CRISPR Therapeutics were worth $593,000 as of […] - 2025-02-21 08:38:56
Vontobel Holding Ltd. Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP): Vontobel Holding Ltd. trimmed its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 11.1% during the 4th quarter, Holdings Channel.com reports. The firm owned 15,068 shares of the company’s stock after selling 1,889 shares during the period. Vontobel Holding Ltd.’s holdings in CRISPR Therapeutics were worth $593,000 as of its most recent SEC […] - 2025-02-20 09:08:52
Citigroup Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $82.00: CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report released on Tuesday morning,Benzinga reports. Citigroup currently has a buy rating on the stock. Several other brokerages have also recently weighed in on CRSP. Needham & Company LLC reiterated a “buy” rating and set a […] - 2025-02-19 10:14:57
Valeo Financial Advisors LLC Reduces Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP): Valeo Financial Advisors LLC reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 15.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,358 shares of the company’s stock after selling 1,175 shares during the period. Valeo Financial Advisors LLC’s holdings […] - 2025-02-19 09:38:55
CRISPR Therapeutics Target of Unusually Large Options Trading (NASDAQ:CRSP): CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) saw unusually large options trading on Tuesday. Stock traders bought 13,128 call options on the stock. This is an increase of approximately 59% compared to the average volume of 8,282 call options. Insiders Place Their Bets In other news, CEO Samarth Kulkarni sold 15,000 shares of the […] - 2025-02-19 08:59:33
Brokerages Set CRISPR Therapeutics AG (NASDAQ:CRSP) Target Price at $74.50: CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus rating of “Moderate Buy” from the twenty-two analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average […] - 2025-02-19 06:46:55
CRISPR Therapeutics (NASDAQ:CRSP) Earns Buy Rating from HC Wainwright: HC Wainwright reissued their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $65.00 price objective on the stock. Several other research analysts have also commented on the stock. Truist Financial lifted their price target on shares […] - 2025-02-16 10:49:00
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded at StockNews.com: StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) to a sell rating in a research report released on Thursday. Other analysts have also issued reports about the stock. Needham & Company LLC reissued a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday. […] - 2025-02-16 10:48:55
CRISPR Therapeutics (NASDAQ:CRSP) Given New $120.00 Price Target at Truist Financial: CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price target points to a potential upside of 175.93% from the stock’s previous close. […] - 2025-02-14 09:16:56

CRSP institutional holdings

The following institutional investment holdings of CRSP have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 52,146 USD 1,884,556

2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 9,503 USD 343,438

2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 40,847 USD 1,476,211

2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 40,847 USD 1,476,211 5.2%

2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 189 USD 6,830

Total = 143,532 USD 5,187,246
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	52,146	USD 1,884,556
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	9,503	USD 343,438
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	40,847	USD 1,476,211
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	40,847	USD 1,476,211 5.2%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	189	USD 6,830
Total =	143,532	USD 5,187,246

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.